Restoration of human immunodeficiency virus-1-specific responses in patients changing from protease to non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy

Scandinavian Journal of Immunology

Volumn 57, Issue 6, 2003, Pages 600-607

  Sullivan, A K ^b   Burton, C T ^a   Nelson, M R ^b   Moyle, G ^b   Mandalia, S ^b   Gotch, F M ^a   Gazzard, B G ^b   Imami, N ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DNA; EFAVIRENZ; INTERLEUKIN 2; PROTEINASE INHIBITOR; RECOMBINANT ANTIGEN; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CYTOKINE PRODUCTION; DNA DETERMINATION; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG RESPONSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MEASUREMENT; PRIORITY JOURNAL; STIMULATION; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DNA, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INTERLEUKIN-2; INTERLEUKIN-4; LONGITUDINAL STUDIES; LYMPHOCYTE ACTIVATION; PROVIRUSES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TIME FACTORS; VIREMIA;

EID: 0038717058     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2003.01276.x     Document Type: Article

References (51)

1. Egger M, Hirschel B, Francioli P et al. Impact of new antiretroviral combination therapies in HIV-infected patients in Switzerland: prospective multicentre study, Swiss HIV Cohort Study. BMJ 1997;315:1194-9.
2. Cameron DW, Heath-Chiozzi M, Danner S et al. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. The advanced HIV Disease Ritonavir Study Group. Lancet 1998;351:543-9.
3. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less: AIDS Clin Trials Group 320 Study Team. N Engl J Med 1997;337:725-33.
4. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Invest. N Engl J Med 1998;338:853-60.
5. Detels R, Munoz A, McFarlane G et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration: Multicenter AIDS Cohort Study Invest. JAMA 1998;280:1497-503.
6. Pozniak A, Gazzard B, Babiker A et al. British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001;2:276-313.
7. Arno A, Ruiz L, Juan M et al. Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years. AIDS 1998;12:697-704.
8. Pakker NG, Nottermans DW, de Boer RJ et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nature Med 1998;4:208-14.
9. + T-cell repopulation of lymphoid tissue after treatment of HIV-1 infection. PNAS USA 1998;95:1154-9.
10. Gill J, Moyle G, Nelson M. Discontinuation of Mycobacterium avium complex prophylaxis in patients with a rise in CD4 count following highly active anti-retroviral therapy. AIDS 1998;12:680.
11. El-Sadr WM, Burman WJ, Grant LB. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. N Engl J Med 2000;342:1085-92.
12. Furrer H, Egger M, Opravil M et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy: Swiss HIV Cohort Study. N Engl J Med 1999;340:1301-6.
13. Jouan M, Saves M, Tubiana R et al. A multicenter prospective study to evaluate the discontinuation of maintenance therapy for CMV retinitis in HIV-patients receiving HAART. AIDS 1999;15:23-31.
14. Lebbe C, Blum L, Pellet C et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998;12:45-49.
15. Martinelli C, Zazzi M, Ambu S, Bartolozzi D, Corsi P, Leoncini F. Complete regression of AIDS-related Kaposi's sarcoma-associated herpesvirus-8 during therapy with indinavir. AIDS 1998;12:1717-9.
16. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:51-58.
17. Sullivan AK, Feher MD, Nelson MR, Gazzard BG. Marked hypertriglyceridaemia associated with ritonavir therapy. AIDS 1998;12:1393-5.
18. Carr A, Miller J, Law M et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000;14:25.
19. Eastone JA, Decker CF. New-onset diabetes mellitus associated with the use of protease inhibitor. Ann Intern Med 1997;127:948.
20. Bonnet F, Saves M, Droz C et al. Increase of atherogenic plasma profile in HIV-infected patients treated with prorease inhibitor-containing regimens. J Acquir Immune Defic Syndr 2000;25:199-200.
21. Henry K, Melroe H, Huebsch J et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351:1328.
22. Sullivan AK, Nelson M, Moyle G, Newell A, Feher M, Gazzard BG. Coronary artery disease occurring with protease inhibitor therapy. Int J STD AIDS 1998;9:711-2.
23. Staszewski S, Morales-Ramirez J, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999;341:1865-73.
24. D'Aquila RT, Hughes MD, Johnson VA et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;124:1019-30.
25. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7.
26. Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol 1996;70:7894-9.
27. Richman DD, Havlir D, Corbeil J et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-6.
28. Condra JH, Emini EA, Gotlib L et al. Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrob Agents Chemother 1992;36:1441-6.
29. Al-Harthi L, Siegal J, Spritzler J et al. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS 2000;14:761-70.
30. + T-cell responses associated with control of viremia. Science 1997;278:1447.
31. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-9.
32. + T-cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
33. + T-cell function mirrors viral load reduction after highly active antiretroviral therapy in patients with advanced HIV disease. Lancer 1998;351:1682-6.
34. Douek DC, McFarland RD, Keiser PH et al. Changes in thymic output with age and during the treatment of HIV infection. Nature 1998;396:690-5.
35. Murphy RL, Smith WJ. Switch studies: a review. HIV Med 2002;3:146-55.
36. Gatell JM. Early antiretroviral therapy: rationale, protease inhibitor-sparing regimens and once daily dosing. Antiviral Ther 1998;3 (Suppl. 4):49-53.
37. Raffi F, Bonnet B, Ferre V et al. Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA. Clin Infect Dis 2000;31:1274-8.
38. Barreiro P, Soriano V, Blanco F et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000;14:807-12.
39. Martinez E, Conget I, Lozano L, Casamitijan R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805-10.
40. Andre P, Groettrup M, Kleinerman P et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T-cell responses. PNAS 1998;95:13120-4.
41. Chavan S, Kodoth S, Pahwa R, Pahwa S. The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and -uninfected individuals. Blood 2001;98:383-9.
42. Burton CT, Hardy GAD, Sullivan AK et al. Impact of NNRTI compared to PI-based highly active antiretroviral therapy on CCR5 receptor expression, α-chemokines and IL-16 secretion in HIV-1 infection. Clin Exp Immunol 2002;130:286-92.
43. Imami N, Larche M, Ritter MA. Inhibition of alloreactivity by MoAb MR6. Differential effects on IL-2 and IL-4 producing human T cells. Int Immunol 1994;6:1575-84.
44. Imami N, Hardy GAD, Nelson MR, Gazzard B, Gotch F. Induction of HIV-1-specific T-cell responses by administration of cytokines in late-stage patients receiving highly active antiretroviral therapy. Clin Exp Immunol 1999;118:78-86.
45. Fessel WJ, Krowka JF, Sheppard HW, Gesner M. Dissociation of immunologic and virologic responses to highly active antiretroviral therapy. J Aquir Immun Defic Syndr 2000;23:314-20.
46. Imami N, Hardy G, Burton C et al. Immune responses and reconstitution in HIV-1 infected individuals: impact of antiretroviral therapy, cytokines and therapeutic vaccination. Immunol Lett 2001;79:63-76.
47. Hardy GAD, Imami N, Sullivan A et al. T lymphocyte function in HIV-1 infection: effects of highly active antiretroviral therapy. Immunol 1999;98 (Suppl. 1):63. (Abstract). 21.3.
48. Gotch F, Hardy G, Imami N. Therapeutic vaccines in HIV-1 infection. Immunol Rev 1999;170:173-82.
49. Moss RB, Wallace MR, Giermakowska WK et al. Phenotypic analysis of human immunodeficiency virus type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen. J Infect Dis 1999;180:641-8.
50. Turner JL, Kostman JR, Aquino A et al. The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs. HIV Med 2001;2:68-77.
51. 6/L CD4 cell counts. JAMA 2000;284:2193-202.